Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995062 | 0.76 | P2RX7 (0.47) | P2RX7MAPTTP53LMNA | |
| SCHEMBL16995068 | 0.76 | P2RX7 (0.55) | P2RX7MAPT | |
| SCHEMBL16995127 | 0.75 | P2RX7 (0.59) | P2RX7MAPTTHRBTP53LMNA | |
| SCHEMBL16986270 | 0.74 | P2RX7 (1.00) | P2RX7MAPTTHRB | |
| SCHEMBL16995129 | 0.73 | DPP4 (0.48) | P2RX7MAPTLMNA | |
| SCHEMBL18371710 | 0.71 | P2RX7 (0.57) | P2RX7MAPTTHRBTP53LMNA | |
| SCHEMBL16995124 | 0.70 | P2RX7 (0.54) | P2RX7MAPTTHRBLMNA | |
| SCHEMBL16995087 | 0.70 | P2RX7 (0.54) | P2RX7MAPTLMNA | |
| SCHEMBL16995128 | 0.69 | P2RX7 (0.46) | P2RX7MAPTTHRBTP53LMNA | |
| SCHEMBL16995110 | 0.69 | P2RX7 (0.57) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2019-01-01 | — | — | US | disclosed |
| EP-3102573-B1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-01-12 | — | — | US | disclosed |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-01-12 | — | — | US | disclosed |
| EP-2905282-A1 | Substituted thiazole or oxazole as P2X7 receptor antagonists | AXXAM S.p.A. (IT) | 2015-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885MAPT 3993/4885THRB 569/4885 |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885MAPT 3993/4885THRB 569/4885 |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885MAPT 4022/4885THRB 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.